LifeMD, Inc. (LFMD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$3.08+0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · LFMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue scaling revenue with focus on longer-duration subscriptions, branded therapies, and expanding growth channels to reach $205.5M-$212.5M revenue in 2026.
Stated as a priority in 3 of last 3 quarters. Revenue guidance was revised downward from $220M-$230M to $205.5M-$212.5M for 2026, with Q2 revenue at $47.3M within guidance and an expected Q4 exit run rate of $250M. The trajectory shows continued growth but below earlier guidance, reflecting mixed delivery.
“Revising full year 2026 guidance to revenue of $205.5 million to $212.5 million”
“Affirming full year 2026 guidance for revenue of $220 million to $230 million”
“For the full year 2025, guidance reflects revenue in the range of $192 million to $193 million”
Focus on cost savings, scaling recurring revenue, and operational efficiencies to improve adjusted EBITDA to negative $6M to breakeven for full year 2026.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA loss improved sequentially from $4.5M in Q1 to $3.5M in Q2 2026, but full year guidance was revised downward from $12M-$17M positive to negative $6M to breakeven. The trajectory shows progress but with a significant downward revision, indicating mixed delivery.
“Adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially”
“Adjusted EBITDA loss was $4.5 million, above and in line with guidance”
“Adjusted EBITDA guidance for 2026 in the range of $12 million to $17 million”
Grow through new strategic collaborations and product launches, including telehealth co-marketing and pharmacy expansion in men’s and women’s health segments.
Stated as a priority in 2 of last 3 quarters. The company launched a telehealth co-marketing collaboration for XYOSTED in Q2 2026 and reported improving Women’s Health trends with new product launches planned. These initiatives show early delivery and ongoing focus.
“Launched exclusive telehealth co-marketing collaboration with Halozyme for XYOSTED”
“Multiple strategic partnerships and new product launches in men’s and women’s health expected in coming months”
Implement a direct-to-patient self-pay program for XYOSTED testosterone injection, initially available in 37 states starting July 2026.
Newly stated in 2026-Q2. The company announced the launch of a direct-to-patient self-pay program for XYOSTED injection starting July 2026 in 37 states. This is a new strategic initiative with no prior quarters for comparison.
“Announced strategic co-marketing collaboration for XYOSTED self-pay program launching July 2026”
Continue growing total revenue to the guided range of $220 million to $230 million for fiscal year 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 0.71x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.